Answers are grounded in this paper and cite their sources.
Review demonstrates significant disease burden and vaccine progress in older adults, highlighting the need for real-world safety and effectiveness studies.
RSV is associated with a significant burden in older adults. While the landscape of RSV prevention in older adults is promising with the licensure of vaccines from two companies, current trial data underscore the need for additional studies. Addressing the real-world effectiveness of these vaccines, understanding potential rare side effects, and ensuring broad inclusivity in future trials are crucial steps to maximize their potential benefits.
No takes yet. Share an insight, caveat, or question.
Kenmoe et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: